Literature DB >> 3309578

Evaluation of the experimental pathogenicity of some Cryptococcus species in normal and cyclophosphamide-immunodepressed mice.

F De Bernardis1, E Palliola, R Lorenzini, G Antonucci.   

Abstract

The pathogenic potential of distinct Cryptococcus species has been evaluated in mice rendered leukopenic by one or two injections of the potent immunosuppressive drug cyclophosphamide (Cy). Pathogenicity assessment included enumeration of viable cryptococcal cells in animal organs and histopathological observations. It was found that putatively non-pathogenic species of Cryptococcus, in particular C. cereanus and C. albidus, showed significant lethality for Cy-treated mice. In Cy-immunodepressed mice, challenged with the infectious cryptococcal cells two days after pharmacological treatment, a significant decrease of LD50 (equivalent to at least one order of magnitude) was observed for all Cryptococcus species. However, the pathogenicity enhancement due to Cy immunodepression was greater with C. neoformans. In all cases, brain and kidney were the most invaded tissues as also evidenced by histopathological examination, which showed the typical cystic lesion. All the observations made point to the conclusion that the pathogenic potential, for the immunomodulated host, of Cryptococci other than C. neoformans is significant being quantitatively and not qualitatively different from that of C. neoformans, as evidenced by a similar organotropism and similar type of histological lesions in the target organs (brain and kidney).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3309578     DOI: 10.1111/j.1348-0421.1987.tb03107.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  5 in total

1.  Cryptococcus neoformans, Candida albicans, and other fungi bind specifically to the glycosphingolipid lactosylceramide (Gal beta 1-4Glc beta 1-1Cer), a possible adhesion receptor for yeasts.

Authors:  V Jimenez-Lucho; V Ginsburg; H C Krivan
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

2.  In vitro and in vivo antifungal activities of BMY-28864, a water-soluble pradimicin derivative.

Authors:  M Kakushima; S Masuyoshi; M Hirano; M Shinoda; A Ohta; H Kamei; T Oki
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Enhanced resistance against Escherichia coli infection by subcutaneous administration of the hot-water extract of Chlorella vulgaris in cyclophosphamide-treated mice.

Authors:  F Konishi; K Tanaka; S Kumamoto; T Hasegawa; M Okuda; I Yano; Y Yoshikai; K Nomoto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Evaluation of the experimental inoculation of Cryptococcus albidus and Cryptococcus laurentii in normal mice: virulence factors and molecular profile before and after animal passage.

Authors:  Reginaldo dos Santos Pedroso; Joseane Cristina Ferreira; Marco Aurélio Sicchiroli Lavrador; Claudia Maria Leite Maffei; Regina Celia Candido
Journal:  Mycopathologia       Date:  2009-04-11       Impact factor: 2.574

Review 5.  Immune Relevant and Immune Deficient Mice: Options and Opportunities in Translational Research.

Authors:  Enrico Radaelli; Sara F Santagostino; Rani S Sellers; Cory F Brayton
Journal:  ILAR J       Date:  2018-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.